Anemia and fatigue in cancer patients

Cancer

Volumn 92, Issue 6 SUPPL., 2001, Pages 1719-1724

  Glaspy, John ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HEMOGLOBIN; INTERLEUKIN 1BETA; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA;

ANEMIA; CANCER; CANCER PATIENT; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FATIGUE; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

EID: 0035883660     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010915)92:6+<1719::aid-cncr1503>3.0.co;2-5     Document Type: Conference Paper

References (35)

1. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: Results of a tripart assessment survey
2. Recombinant human erythropoietin in anemic patients with end-stage renal disease: Results of a phase III multicenter clinical trial
3. Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients
4. Improvements in quality, of life following treatment with r-HuEPO in anemic hemodialysis patients
5. Erythropoietin treatment improves quality of life in hemodialysis patients
6. Recombinant human erythropoietin and the quality of life of end-stage renal disease patients: A comparative analysis
7. The use of generic and specific quality-of-life measures in hemodialysis patients treated with eryrhropoietin
8. Effect of long-term epoetin beta therapy on the quality of life of hemodialysis patients
9. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis
10. National Cooperative rHu Erythropoietin Study in patients with chronic renal failure: An interim report
11. Long-term effects on quality of life in haemodialysis patients of correction of anaemia with erythropoietin
12. Effect of erythropoietin (rHuEPO) on trace elements and quality of life (Qol) in chronic hemodialysis patients
13. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients
14. Quality of life and hematocrit level
15. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: A double-blind, placebo-controlled trial
16. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients
17. Recombinant human erythropoietin in predialysis patients
18. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients
19. Quality of life improvements in CAPD patients treated with subcutaneously administered erythropoietin for anemia
20. Non-cardiac benefits of human recombinant erythropoietin in end stage renal failure and anaemia
21. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin
22. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy: Overview of four clinical trials
23. Recombinant human erythropoietin and health-related quality of life of AIDS patients with anemia
24. Recombinant human erythropoietin treatment in cisplatin-associated anemia: A randomized, double-blind trial with placebo
25. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer
26. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy
27. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: Results of double-blind and open-label follow-up studies
28. Recombinant human erythropoietin in the treatment of the anaemia of cancer
29. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin
30. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy
31. Transfusion requirements of children with cancer and the use of human recombinant erythropoietin for the prevention and treatment of cytostatics induced anemia in children
32. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
33. The impact of epoetin alfa on quality of life during cancer chemotherapy: A fresh look at an old problem
34. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study
35. Identifying hemoglobin level for optimal quality of life: Results of an incremental analysis